Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

accelerated approval

(ak-SEH-leh-ray-ted uh-PROO-vul)
An official process that allows a new drug to be approved by the U.S. Food and Drug Administration (FDA) before it has gone through all of the required levels of testing in humans. It is only used for drugs that treat serious or life-threatening diseases for which other treatments may not be available or may no longer be effective. A drug may be approved through the accelerated approval process if it has shown certain signs in clinical trials that it might be beneficial for patients, such as a shrinking tumor. Further testing of the drug is required after it has received accelerated approval and is on the market to confirm that it really works. Accelerated approval is one way that patients can receive promising new drugs when other treatment options may not exist.
Search NCI's Dictionary of Cancer Terms